Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodality Therapy for High-Risk Thymoma
NCT00387868Phase 2Completed
- Sponsor
- The Valley Health System
- Start
- Oct 2006
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and etoposide in thymoma and thymic carcinoma (TC), sponsored by The Valley Health System. Primary endpoint: Pathological Complete Response Rate at 16 weeks. Started Oct 2006; status: completed.
02
Drugs
cisplatinetoposide
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT00387868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387868.